中生製藥(01177.HK)附屬治療新冠肺炎藥物完成臨床試驗註冊備案登記
中生製藥(01177.HK)公布,根據中國臨床試驗註冊中心官網公開信息,甘草酸二銨腸溶膠囊聯用維生素C片在治療新型冠狀病毒肺炎的有效性和安全性的臨床研究,已完成臨床試驗註冊備案登記。
甘草酸二銨腸溶膠囊由附屬公司正大天晴藥業研製,現在其對新型冠狀病毒肺炎的療效亦受到關注。上述臨床研究乃建基於:新型冠狀病毒繁殖過程中會產生大量的氧自由基損傷患者的重要器官,使用維生素C去抗氧自由基,配合甘草酸的即抗炎又不抑制免疫的療效,對組織器官可發揮雙重保護作用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.